{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:02:26Z","timestamp":1789387346609,"version":"build-2803163510"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"DOI":"10.1007\/s40259-026-00808-7","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:38:13Z","timestamp":1789378693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the Prevention of Anti-drug Antibody Formation with Uricase Therapy: Mechanistic Roles of DMARDs in Modifying Gout Flare Risk"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0897-2272","authenticated-orcid":false,"given":"Ted R.","family":"Mikuls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-1711","authenticated-orcid":false,"given":"Tuhina","family":"Neogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7365-7212","authenticated-orcid":false,"given":"Angelo","family":"Gaffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"808_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113126","volume":"151","author":"R Ben Mrid","year":"2022","unstructured":"Ben Mrid R, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti-rheumatoid drugs advancements: new insights into the molecular treatment of rheumatoid arthritis. Biomed Pharmacother. 2022;151:113126.","journal-title":"Biomed Pharmacother"},{"key":"808_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100150","volume":"5","author":"NP Duarte-Delgado","year":"2022","unstructured":"Duarte-Delgado NP, Cala MP, Barreto A, Rodriguez CL. Metabolites and metabolic pathways associated with rheumatoid arthritis and systemic lupus erythematosus. J Transl Autoimmun. 2022;5:100150.","journal-title":"J Transl Autoimmun."},{"key":"808_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40259-021-00507-5","volume":"35","author":"SJ Bots","year":"2021","unstructured":"Bots SJ, Parker CE, Brandse JF, Lowenberg M, Feagan BG, Sandborn WJ, et al. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2021;35:715\u201333.","journal-title":"BioDrugs"},{"key":"808_CR4","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/art.41731","volume":"73","author":"PP Khanna","year":"2021","unstructured":"Khanna PP, Khanna D, Cutter G, Foster J, Melnick J, Jaafar S, et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73:1523\u201332.","journal-title":"Arthritis Rheumatol"},{"key":"808_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.42335","volume":"75","author":"JK Botson","year":"2023","unstructured":"Botson JK, Saag K, Peterson J, Parikh N, Ong S, La D, et al. A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings. Arthritis Rheumatol. 2023;75:293\u2013304.","journal-title":"Arthritis Rheumatol"},{"key":"808_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40744-021-00421-w","volume":"9","author":"KR Masri","year":"2022","unstructured":"Masri KR, Padnick-Silver L, Winterling K, LaMoreaux B. Effect of leflunomide on pegloticase response rate in patients with uncontrolled gout: a retrospective study. Rheumatol Ther. 2022;9:555\u201363.","journal-title":"Rheumatol Ther"},{"key":"808_CR7","unstructured":"Baraf HSB, Rainey H, Lipsky P. The impact of azathioprine on the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout. Arthritis Rheumatol. 2020;72(suppl 10):0685."},{"key":"808_CR8","unstructured":"KRYSTEXXA (pegloticase) injection, for intravenous use. 2026. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Krystexxa\/Krystexxa_fpi_english.pdf. Accessed 3 Sep 2026."},{"key":"808_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/art.70266","author":"HSB Baraf","year":"2026","unstructured":"Baraf HSB, Khanna PP, Petronijevic M, Lortkipanidze M, Patel A, Ayesu K, et al. Efficacy and safety of nanoencapsulated sirolimus plus pegadricase: results from the randomized, placebo-controlled phase 3 trials. Arthritis Rheumatol. 2026. https:\/\/doi.org\/10.1002\/art.70266.","journal-title":"Arthritis Rheumatol"},{"key":"808_CR10","doi-asserted-by":"publisher","first-page":"e239501","DOI":"10.1001\/jamanetworkopen.2023.9501","volume":"6","author":"C Yokose","year":"2011","unstructured":"Yokose C, McCormick N, Lu N, Tanikella S, Lin K, Joshi AD, et al. Trends in prevalence of gout among US Asian adults, 2011\u20132018. JAMA Netw Open. 2011;6:e239501.","journal-title":"JAMA Netw Open"},{"key":"808_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"PP Khanna","year":"2012","unstructured":"Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117.","journal-title":"Health Qual Life Outcomes"},{"key":"808_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA. 2022;328:440\u201350.","journal-title":"JAMA"},{"key":"808_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40744-020-00260-1","volume":"8","author":"M Francis-Sedlak","year":"2021","unstructured":"Francis-Sedlak M, LaMoreaux B, Padnick-Silver L, Holt RJ, Bello AE. Characteristics, comorbidities, and potential consequences of uncontrolled gout: an insurance-claims database study. Rheumatol Ther. 2021;8:183\u201397.","journal-title":"Rheumatol Ther"},{"key":"808_CR14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3899\/jrheum.2023-0706","volume":"51","author":"LK Stamp","year":"2024","unstructured":"Stamp LK, Dalbeth N. What is allopurinol failure and what should we do about it? J Rheumatol. 2024;51:556\u201362.","journal-title":"J Rheumatol"},{"key":"808_CR15","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72:744\u201360.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"808_CR16","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/art.23803","volume":"58","author":"NL Edwards","year":"2008","unstructured":"Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum. 2008;58:2587\u201390.","journal-title":"Arthritis Rheum"},{"key":"808_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40744-024-00697-8","volume":"11","author":"V Strand","year":"2024","unstructured":"Strand V, Pillinger MH, Oladapo A, Yousefian C, Brooks D, Kragh N. Patient experience with chronic refractory gout and its impact on health-related quality of life: literature review and qualitative analysis. Rheumatol Ther. 2024;11:1271\u201390.","journal-title":"Rheumatol Ther"},{"key":"808_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40259-022-00517-x","volume":"36","author":"N Schlesinger","year":"2022","unstructured":"Schlesinger N, Padnick-Silver L, LaMoreaux B. Enhancing the response rate to recombinant uricases in patients with gout. BioDrugs. 2022;36:95\u2013103.","journal-title":"BioDrugs"},{"key":"808_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177877","volume":"12","author":"W Li","year":"2017","unstructured":"Li W, Xu S, Zhang B, Zhu Y, Hua Y, Kong X, et al. Directed evolution to improve the catalytic efficiency of urate oxidase from Bacillus subtilis. PLoS ONE. 2017;12:e0177877.","journal-title":"PLoS ONE"},{"key":"808_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41584-023-01006-3","volume":"19","author":"N Schlesinger","year":"2023","unstructured":"Schlesinger N, Perez-Ruiz F, Liote F. Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol. 2023;19:640\u20139.","journal-title":"Nat Rev Rheumatol"},{"key":"808_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711\u201320.","journal-title":"JAMA"},{"key":"808_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41467-021-27945-7","volume":"13","author":"E Sands","year":"2022","unstructured":"Sands E, Kivitz A, DeHaan W, Leung SS, Johnston L, Kishimoto TK. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nat Commun. 2022;13:272.","journal-title":"Nat Commun"},{"key":"808_CR23","unstructured":"ELITEK (rasburicase) for injection, for intravenous use. 2025. https:\/\/products.sanofi.us\/elitek\/Elitek.pdf. Accessed 3 Sep 2026."},{"key":"808_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1742395310378761","volume":"6","author":"LR Harrold","year":"2010","unstructured":"Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chron Illn. 2010;6:263\u201371.","journal-title":"Chron Illn"},{"key":"808_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40744-023-00546-0","volume":"10","author":"A Kivitz","year":"2023","unstructured":"Kivitz A, DeHaan W, Azeem R, Park J, Rhodes S, Inshaw J, et al. Phase 2 dose-finding study in patients with gout using SEL-212, a novel PEGylated uricase (SEL-037) combined with tolerogenic nanoparticles (SEL-110). Rheumatol Ther. 2023;10:825\u201347.","journal-title":"Rheumatol Ther"},{"key":"808_CR26","doi-asserted-by":"publisher","first-page":"100504","DOI":"10.1016\/j.clinme.2025.100504","volume":"25","author":"R Singh","year":"2025","unstructured":"Singh R, Croft AP. Navigating complications of disease-modifying anti-rheumatic drugs at the \u2018front door.\u2019 Clin Med (Lond). 2025;25:100504.","journal-title":"Clin Med (Lond)"},{"key":"808_CR27","doi-asserted-by":"crossref","unstructured":"Gao Y, Zhang Y, Liu X. Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm (2020). 2024;5:e509.","DOI":"10.1002\/mco2.509"},{"key":"808_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/art.43215","volume":"77","author":"R Poulsen","year":"2025","unstructured":"Poulsen R, Dalbeth N. Gout and NLRP3 inflammasome biology. Arthritis Rheumatol. 2025;77:1317\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"808_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.931690","volume":"13","author":"H Yin","year":"2022","unstructured":"Yin H, Liu N, Sigdel KR, Duan L. Role of NLRP3 inflammasome in rheumatoid arthritis. Front Immunol. 2022;13:931690.","journal-title":"Front Immunol"},{"key":"808_CR30","unstructured":"KINERET\u00ae (anakinra) injection, for subcutaneous use. 2025. https:\/\/kineretrxhcp.com\/pdf\/Full-Prescribing-Information-English.pdf. Accessed 3 Sep 2026."},{"key":"808_CR31","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.ard.2025.06.503","volume":"84","author":"O Troum","year":"2025","unstructured":"Troum O, Botson J, Fang F, Obermeyer K, Mohammad A, Verma S, et al. Safety and efficacy of monthly dosing of pegloticase (every 4 weeks) with methotrexate co-administration in patients with uncontrolled gout: phase 4 FORWARD open-label trial. Ann Rheum Dis. 2025;84:1225\u20136.","journal-title":"Ann Rheum Dis"},{"key":"808_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/annrheumdis-2015-eular.2595","volume":"74(Suppl 2)","author":"JJ Lee","year":"2015","unstructured":"Lee JJ, Bykerk VP, Dresser GK, Boire G, Haraoui B, Hitchon C, et al, on behalf of the CATCH Investigators. THU0149 Does methotrexate lower serum uric acid levels? Data from the CATCH cohort. Ann Rheum Dis. 2015;74:248.","journal-title":"Ann Rheum Dis"},{"key":"808_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16:145\u201354.","journal-title":"Nat Rev Rheumatol"},{"key":"808_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/bj3420143","volume":"342","author":"LD Fairbanks","year":"1999","unstructured":"Fairbanks LD, Rueckemann K, Qiu Y, Hawrylowicz CM, Richards DF, Swaminathan R, et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J. 1999;342:143\u201352.","journal-title":"Biochem J"},{"key":"808_CR35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.bjp.0705054","volume":"138","author":"DC Phillips","year":"2003","unstructured":"Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol. 2003;138:501\u201311.","journal-title":"Br J Pharmacol"},{"key":"808_CR36","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/art.42644","volume":"77","author":"JK Park","year":"2025","unstructured":"Park JK, Lee YJ, Kang EH, Shin K, Kim MJ, Ha Y-J, et al. Effect of the methotrexate discontinuation for 1 versus 2 weeks on vaccine response to seasonal influenza vaccine in rheumatoid arthritis: a noninferiority randomized controlled trial. Arthritis Rheumatol. 2025;77:1276\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"808_CR37","doi-asserted-by":"publisher","first-page":"e004664","DOI":"10.1136\/rmdopen-2024-004664","volume":"10","author":"LYL Kummer","year":"2024","unstructured":"Kummer LYL, Fernandez Blanco L, Kreher C, Bos A, Kuijper LH, Verstegen NJM, et al. Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID. RMD Open. 2024;10:e004664.","journal-title":"RMD Open"},{"key":"808_CR38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","volume":"86","author":"B Friedman","year":"2019","unstructured":"Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86:301\u20137.","journal-title":"Joint Bone Spine"},{"key":"808_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41467-022-28086-1","volume":"13","author":"RC Levack","year":"2022","unstructured":"Levack RC, Newell KL, Cabrera-Martinez B, Cox J, Perl A, Bastacky SI, et al. Adenosine receptor 2a agonists target mouse CD11c(+)T-bet(+) B cells in infection and autoimmunity. Nat Commun. 2022;13:452.","journal-title":"Nat Commun"},{"key":"808_CR40","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/art.40796","volume":"71","author":"SE Schmiel","year":"2019","unstructured":"Schmiel SE, Kalekar LA, Zhang N, Blankespoor TW, Robinson LJ, Mueller DL. Adenosine 2a receptor signal blockade of murine autoimmune arthritis via inhibition of pathogenic germinal center-follicular helper T cells. Arthritis Rheumatol. 2019;71:773\u201383.","journal-title":"Arthritis Rheumatol"},{"key":"808_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2007-03-081646","volume":"111","author":"PE Zarek","year":"2008","unstructured":"Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood. 2008;111:251\u20139.","journal-title":"Blood"},{"key":"808_CR42","doi-asserted-by":"publisher","first-page":"1463429","DOI":"10.3389\/fimmu.2024.1463429","volume":"15","author":"A Krawczyk","year":"2024","unstructured":"Krawczyk A, Kravcenia B, Maslanka T. Mycophenolate mofetil: an update on its mechanism of action and effect on lymphoid tissue. Front Immunol. 2024;15:1463429.","journal-title":"Front Immunol"},{"key":"808_CR43","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/ard.59.11.841","volume":"59","author":"FC Breedveld","year":"2000","unstructured":"Breedveld FC, Dayer J-M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59:841\u20139.","journal-title":"Ann Rheum Dis"},{"key":"808_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115706","volume":"168","author":"X Diaz-Villamarin","year":"2023","unstructured":"Diaz-Villamarin X, Fernandez-Varon E, Rojas Romero MC, Callejas-Rubio JL, Cabeza-Barrera J, Rodriguez-Nogales A, et al. Azathioprine dose tailoring based on pharmacogenetic information: insights of clinical implementation. Biomed Pharmacother. 2023;168:115706.","journal-title":"Biomed Pharmacother"},{"key":"808_CR45","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1053-2498(01)00335-7","volume":"21","author":"ML Rose","year":"2002","unstructured":"Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant. 2002;21:282\u20135.","journal-title":"J Heart Lung Transplant"},{"key":"808_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107434","volume":"93","author":"H Huang","year":"2021","unstructured":"Huang H, Ran H, Liu X, Yu L, Qiu L, Lin Z, et al. Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses. Int Immunopharmacol. 2021;93:107434.","journal-title":"Int Immunopharmacol"},{"key":"808_CR47","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0022-3565(24)38030-9","volume":"288","author":"Y Mizushima","year":"1999","unstructured":"Mizushima Y, Amano Y, Kitagawa H, Ogata K. Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model. J Pharmacol Exp Ther. 1999;288:849\u201357.","journal-title":"J Pharmacol Exp Ther"},{"key":"808_CR48","doi-asserted-by":"publisher","first-page":"29682","DOI":"10.1074\/jbc.270.50.29682","volume":"270","author":"LD Fairbanks","year":"1995","unstructured":"Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. J Biol Chem. 1995;270:29682\u20139.","journal-title":"J Biol Chem"},{"key":"808_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-015-0603-8","volume":"17","author":"T Fassbinder","year":"2015","unstructured":"Fassbinder T, Saunders U, Mickholz E, Jung E, Becker H, Schluter B, et al. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res Ther. 2015;17:92.","journal-title":"Arthritis Res Ther"},{"key":"808_CR50","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.4049\/jimmunol.165.5.2374","volume":"165","author":"A Mehling","year":"2000","unstructured":"Mehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000;165:2374\u201381.","journal-title":"J Immunol"},{"key":"808_CR51","doi-asserted-by":"publisher","first-page":"a040592","DOI":"10.1101\/cshperspect.a040592","volume":"13","author":"NS Chandel","year":"2021","unstructured":"Chandel NS. Nucleotide metabolism. Cold Spring Harb Perspect Biol. 2021;13:a040592.\u00a0","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"808_CR52","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/JCI16432","volume":"111","author":"I Tiede","year":"2003","unstructured":"Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133\u201345.","journal-title":"J Clin Invest"},{"key":"808_CR53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/ddc4030036","volume":"4","author":"A Dhiman","year":"2025","unstructured":"Dhiman A, Garkhal K. Leflunomide applicability in rheumatoid arthritis: drug delivery challenges and emerging formulation strategies. Drugs Drug Candid. 2025;4:36.","journal-title":"Drugs Drug Candid"},{"key":"808_CR54","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00007890-199602270-00020","volume":"61","author":"KF Siemasko","year":"1995","unstructured":"Siemasko KF, Chong ASF, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation. 1995;61:635\u201342.","journal-title":"Transplantation"},{"key":"808_CR55","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","volume":"11","author":"TK Kishimoto","year":"2020","unstructured":"Kishimoto TK. Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies. Front Immunol. 2020;11:969.","journal-title":"Front Immunol"},{"key":"808_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03181-w","volume":"25","author":"F Zhang","year":"2023","unstructured":"Zhang F, Cheng T, Zhang SX. Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis. Arthritis Res Ther. 2023;25:187.","journal-title":"Arthritis Res Ther"},{"key":"808_CR57","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1172\/JCI86504","volume":"126","author":"DD Jones","year":"2016","unstructured":"Jones DD, Gaudette BT, Wilmore JR, Chernova I, Bortnick A, Weiss BM, et al. mTOR has distinct functions in generating versus sustaining humoral immunity. J Clin Invest. 2016;126:4250\u201361.","journal-title":"J Clin Invest"},{"key":"808_CR58","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/s41467-017-01602-4","volume":"8","author":"J Sintes","year":"2017","unstructured":"Sintes J, Gentile M, Zhang S, Garcia-Carmona Y, Magri G, Cassis L, et al. mTOR intersects antibody-inducing signals from TACI in marginal zone B cells. Nat Commun. 2017;8:1462.","journal-title":"Nat Commun"},{"key":"808_CR59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41467-019-14032-1","volume":"11","author":"BT Gaudette","year":"2020","unstructured":"Gaudette BT, Jones DD, Bortnick A, Argon Y, Allman D. mTORC1 coordinates an immediate unfolded protein response-related transcriptome in activated B cells preceding antibody secretion. Nat Commun. 2020;11:723.","journal-title":"Nat Commun"},{"key":"808_CR60","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nnano.2016.135","volume":"11","author":"TK Kishimoto","year":"2016","unstructured":"Kishimoto TK, Ferrari JD, LaMothe RA, Kolte PN, Griset AP, O\u2019Neil C, et al. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat Nanotechnol. 2016;11:890\u20139.","journal-title":"Nat Nanotechnol"},{"key":"808_CR61","doi-asserted-by":"publisher","first-page":"E156","DOI":"10.1073\/pnas.1408686111","volume":"112","author":"RA Maldonado","year":"2015","unstructured":"Maldonado RA, LaMothe RA, Ferrari JD, Zhang AH, Rossi RJ, Kolte PN, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci USA. 2015;112:E156\u201365.","journal-title":"Proc Natl Acad Sci USA"},{"key":"808_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637469","volume":"12","author":"PO Ilyinskii","year":"2021","unstructured":"Ilyinskii PO, Roy CJ, LePrevost J, Rizzo GL, Kishimoto TK. Enhancement of the tolerogenic phenotype in the liver by ImmTOR nanoparticles. Front Immunol. 2021;12:637469.","journal-title":"Front Immunol"},{"key":"808_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.33","volume":"2","author":"C Emoto","year":"2013","unstructured":"Emoto C, Fukuda T, Cox S, Christians U, Vinks AA. Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. CPT Pharmacometr Syst Pharmacol. 2013;2:e59.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"808_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/B978-0-12-380995-7.00004-5","volume":"108","author":"RA Maldonado","year":"2010","unstructured":"Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111\u201365.","journal-title":"Adv Immunol"},{"key":"808_CR65","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4078\/jrd.2024.0054","volume":"32","author":"EY Ahn","year":"2025","unstructured":"Ahn EY, So MW. The pathogenesis of gout. J Rheum Dis. 2025;32:8\u201316.","journal-title":"J Rheum Dis"},{"key":"808_CR66","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1073\/pnas.1620910114","volume":"114","author":"TO Crisan","year":"2017","unstructured":"Crisan TO, Cleophas MCP, Novakovic B, Erler K, van de Veerdonk FL, Stunnenberg HG, et al. Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway. Proc Natl Acad Sci USA. 2017;114:5485\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"808_CR67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fimmu.2017.00036","volume":"8","author":"C Pellegrini","year":"2017","unstructured":"Pellegrini C, Antonioli L, Lopez-Castejon G, Blandizzi C, Fornai M. Canonical and non-canonical activation of NLRP3 inflammasome at the crossroad between immune tolerance and intestinal inflammation. Front Immunol. 2017;8:36.","journal-title":"Front Immunol"},{"key":"808_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451176","volume":"55","author":"A Gonzalez-Dominguez","year":"2025","unstructured":"Gonzalez-Dominguez A, Zhang S, Boy-Ruiz D, Connors D, de la Varga-Martinez R, Mock BA, et al. mTOR modulates NLRP3 inflammasome activation via nuclear translocation and STAT1 inhibition. Eur J Immunol. 2025;55:e51176.","journal-title":"Eur J Immunol"},{"key":"808_CR69","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3899\/jrheum.180855","volume":"46","author":"BM Alberts","year":"2019","unstructured":"Alberts BM, Barber JS, Sacre SM, Davies KA, Ghezzi P, Mullen LM. Precipitation of soluble uric acid is necessary for in vitro activation of the NLRP3 inflammasome in primary human monocytes. J Rheumatol. 2019;46:1141\u201350.","journal-title":"J Rheumatol"},{"key":"808_CR70","doi-asserted-by":"publisher","first-page":"39884","DOI":"10.1038\/srep39884","volume":"7","author":"TT Braga","year":"2017","unstructured":"Braga TT, Forni MF, Correa-Costa M, Ramos RN, Barbuto JA, Branco P, et al. Soluble uric acid activates the NLRP3 inflammasome. Sci Rep. 2017;7:39884.","journal-title":"Sci Rep"},{"key":"808_CR71","doi-asserted-by":"publisher","first-page":"1027917","DOI":"10.3389\/fmolb.2022.1027917","volume":"9","author":"G Yang","year":"2022","unstructured":"Yang G, Kang HC, Cho YY, Lee HS, Lee JY. Inflammasomes and their roles in arthritic disease pathogenesis. Front Mol Biosci. 2022;9:1027917.","journal-title":"Front Mol Biosci"},{"key":"808_CR72","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/ni.1631","volume":"9","author":"V Hornung","year":"2008","unstructured":"Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847\u201356.","journal-title":"Nat Immunol"},{"key":"808_CR73","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.bbrc.2019.02.141","volume":"511","author":"SK Kim","year":"2019","unstructured":"Kim SK, Choe JY, Park KY. TXNIP-mediated nuclear factor-kappaB signaling pathway and intracellular shifting of TXNIP in uric acid-induced NLRP3 inflammasome. Biochem Biophys Res Commun. 2019;511:725\u201331.","journal-title":"Biochem Biophys Res Commun"},{"key":"808_CR74","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.1007\/s11033-022-07378-1","volume":"49","author":"P Li","year":"2022","unstructured":"Li P, Kurata Y, Taufiq F, Kuwabara M, Ninomiya H, Higaki K, et al. Kv1.5 channel mediates monosodium urate-induced activation of NLRP3 inflammasome in macrophages and arrhythmogenic effects of urate on cardiomyocytes. Mol Biol Rep. 2022;49:5939\u201352.","journal-title":"Mol Biol Rep"},{"key":"808_CR75","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397:1843\u201355.","journal-title":"Lancet"},{"key":"808_CR76","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2147\/JIR.S460333","volume":"17","author":"C Li","year":"2024","unstructured":"Li C, Wu C, Li F, Xu W, Zhang X, Huang Y, et al. Targeting neutrophil extracellular traps in gouty arthritis: insights into pathogenesis and therapeutic potential. J Inflamm Res. 2024;17:1735\u201363.","journal-title":"J Inflamm Res"},{"key":"808_CR77","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/art.27356","volume":"62","author":"N Dalbeth","year":"2010","unstructured":"Dalbeth N, Pool B, Gamble GD, Smith T, Callon KE, McQueen FM, et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum. 2010;62:1549\u201356.","journal-title":"Arthritis Rheum"},{"key":"808_CR78","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/art.1780360912","volume":"36","author":"E Ortiz-Bravo","year":"1993","unstructured":"Ortiz-Bravo E, Sieck MS, Schumacher HR Jr. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum. 1993;36:1274\u201385.","journal-title":"Arthritis Rheum"},{"key":"808_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2022.213005","volume":"139","author":"C Chen","year":"2022","unstructured":"Chen C, Wang J, Liang Z, Li M, Fu D, Zhang L, et al. Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout. Biomater Adv. 2022;139:213005.","journal-title":"Biomater Adv."},{"key":"808_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000287","volume":"2","author":"JM Kremer","year":"2016","unstructured":"Kremer JM, Lawrence DA, Hamilton R, McInnes IB. Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open. 2016;2:e000287.","journal-title":"RMD Open"},{"key":"808_CR81","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.3390\/ijms19102894","volume":"19","author":"Z Pang","year":"2018","unstructured":"Pang Z, Wang G, Ran N, Lin H, Wang Z, Guan X, et al. Inhibitory effect of methotrexate on rheumatoid arthritis inflammation and comprehensive metabolomics analysis using ultra-performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-Q\/TOF-MS). Int J Mol Sci. 2018;19:2894.","journal-title":"Int J Mol Sci"},{"key":"808_CR82","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D","volume":"43","author":"MC Kraan","year":"2000","unstructured":"Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 2000;43:1820\u201330.","journal-title":"Arthritis Rheum"},{"key":"808_CR83","doi-asserted-by":"publisher","first-page":"1405084","DOI":"10.3389\/fimmu.2024.1405084","volume":"15","author":"W Lang","year":"2024","unstructured":"Lang W, Wen X, Zhang S, Liang X, Chen L, Zhang D, et al. Cynaroside ameliorates methotrexate-induced enteritis in rats through inhibiting NLRP3 inflammasome activation. Front Immunol. 2024;15:1405084.","journal-title":"Front Immunol"},{"key":"808_CR84","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2147\/JIR.S338888","volume":"16","author":"K Manna","year":"2023","unstructured":"Manna K, Khan ZS, Saha M, Mishra S, Gaikwad N, Bhakta JN, et al. Manjari Medika grape seed extract protects methotrexate-induced hepatic inflammation: involvement of NF-kappaB\/NLRP3 and Nrf2\/HO-1 signaling system. J Inflamm Res. 2023;16:467\u201392.","journal-title":"J Inflamm Res"},{"key":"808_CR85","doi-asserted-by":"publisher","first-page":"43101","DOI":"10.1021\/acsomega.5c06335","volume":"10","author":"DM Hal","year":"2025","unstructured":"Hal DM, Mehanna ET, Hazem RM, Swidan S, Elrayess RA, Nashawi AA, et al. Mitigating methotrexate-induced kidney damage in mice by the Phragmanthera austroarabica extract, its major constituent, and its polymeric nanoparticles. ACS Omega. 2025;10:43101\u201319.","journal-title":"ACS Omega"},{"key":"808_CR86","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00011-019-01241-z","volume":"68","author":"SM Abd El-Twab","year":"2019","unstructured":"Abd El-Twab SM, Hussein OE, Hozayen WG, Bin-Jumah M, Mahmoud AM. Chicoric acid prevents methotrexate-induced kidney injury by suppressing NF-kappaB\/NLRP3 inflammasome activation and up-regulating Nrf2\/ARE\/HO-1 signaling. Inflamm Res. 2019;68:511\u201323.","journal-title":"Inflamm Res"},{"key":"808_CR87","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1039\/C9FO00114J","volume":"10","author":"AM Mahmoud","year":"2019","unstructured":"Mahmoud AM, Hussein OE, Abd El-Twab SM, Hozayen WG. Ferulic acid protects against methotrexate nephrotoxicity via activation of Nrf2\/ARE\/HO-1 signaling and PPARgamma, and suppression of NF-kappaB\/NLRP3 inflammasome axis. Food Funct. 2019;10:4593\u2013607.","journal-title":"Food Funct"},{"key":"808_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/ar4444","volume":"16","author":"NJ Olsen","year":"2014","unstructured":"Olsen NJ, Spurlock CF 3rd, Aune TM. Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014;16:R17.","journal-title":"Arthritis Res Ther"},{"key":"808_CR89","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jid.2020.07.012","volume":"141","author":"D Verma","year":"2021","unstructured":"Verma D, Fekri SZ, Sigurdardottir G, Bivik Eding C, Sandin C, Enerback C. Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation. J Invest Dermatol. 2021;141:586\u201395.","journal-title":"J Invest Dermatol"},{"key":"808_CR90","doi-asserted-by":"publisher","first-page":"1107670","DOI":"10.3389\/fimmu.2023.1107670","volume":"14","author":"W Jing","year":"2023","unstructured":"Jing W, Liu C, Su C, Liu L, Chen P, Li X, et al. Role of reactive oxygen species and mitochondrial damage in rheumatoid arthritis and targeted drugs. Front Immunol. 2023;14:1107670.","journal-title":"Front Immunol"},{"key":"808_CR91","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/cmi.2014.65","volume":"12","author":"JJ Jhang","year":"2015","unstructured":"Jhang JJ, Cheng YT, Ho CY, Yen GC. Monosodium urate crystals trigger Nrf2- and heme oxygenase-1-dependent inflammation in THP-1 cells. Cell Mol Immunol. 2015;12:424\u201334.","journal-title":"Cell Mol Immunol"},{"key":"808_CR92","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.redox.2017.07.018","volume":"13","author":"MC Zimmerman","year":"2017","unstructured":"Zimmerman MC, Clemens DL, Duryee MJ, Sarmiento C, Chiou A, Hunter CD, et al. Direct antioxidant properties of methotrexate: inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging. Redox Biol. 2017;13:588\u201393.","journal-title":"Redox Biol"},{"key":"808_CR93","doi-asserted-by":"crossref","unstructured":"Faustino VD, Arias SCA, Ferreira Avila V, Foresto-Neto O, Zambom FFF, Machado FG, et al. Simultaneous activation of innate and adaptive immunity participates in the development of renal injury in a model of heavy proteinuria. Biosci Rep. 2018;38:BSR20180762.","DOI":"10.1042\/BSR20180762"},{"key":"808_CR94","doi-asserted-by":"publisher","first-page":"7680","DOI":"10.3390\/ijms23147680","volume":"23","author":"R Satou","year":"2022","unstructured":"Satou R, Franco M, Dugas CM, Katsurada A, Navar LG. Immunosuppression by mycophenolate mofetil mitigates intrarenal angiotensinogen augmentation in angiotensin II-dependent hypertension. Int J Mol Sci. 2022;23:7680.","journal-title":"Int J Mol Sci"},{"key":"808_CR95","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.4103\/0366-6999.235116","volume":"131","author":"XC Huang","year":"2018","unstructured":"Huang XC, He Y, Zhuang J, He J, Luo GH, Han JC, et al. Mycophenolic acid synergizing with lipopolysaccharide to induce interleukin-1beta release via activation of caspase-1. Chin Med J (Engl). 2018;131:1533\u201340.","journal-title":"Chin Med J (Engl)"},{"key":"808_CR96","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1365-3083.1991.tb03746.x","volume":"33","author":"EM Eugui","year":"1991","unstructured":"Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991;33:161\u201373.","journal-title":"Scand J Immunol"},{"key":"808_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119154","volume":"271","author":"MS Serrya","year":"2021","unstructured":"Serrya MS, El-Sheakh AR, Makled MN. Evaluation of the therapeutic effects of mycophenolate mofetil targeting Nrf-2 and NLRP3 inflammasome in acetic acid induced ulcerative colitis in rats. Life Sci. 2021;271:119154.","journal-title":"Life Sci"},{"key":"808_CR98","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1093\/rheumatology\/keae517","volume":"64","author":"EA Morris","year":"2025","unstructured":"Morris EA, Parvizi R, Orzechowski NM, Whitfield ML, Pioli PA. Mycophenolate mofetil directly modulates myeloid viability and pro-fibrotic activation of human macrophages. Rheumatology (Oxford). 2025;64:3125\u201333.","journal-title":"Rheumatology (Oxford)"},{"key":"808_CR99","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1046\/j.1523-1755.2003.00811.x","volume":"63","author":"E Tapia","year":"2003","unstructured":"Tapia E, Franco M, Sanchez-Lozada LG, Soto V, Avila-Casado C, Santamaria J, et al. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int. 2003;63:994\u20131002.","journal-title":"Kidney Int"},{"key":"808_CR100","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejphar.2012.05.001","volume":"688","author":"S Jiang","year":"2012","unstructured":"Jiang S, Tang Q, Rong R, Tang L, Xu M, Lu J, et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. Eur J Pharmacol. 2012;688:56\u201361.","journal-title":"Eur J Pharmacol"},{"key":"808_CR101","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1002\/jcb.26007","volume":"118","author":"M Nowak","year":"2017","unstructured":"Nowak M, Tardivel S, Nguyen-Khoa T, Abreu S, Allaoui F, Fournier N, et al. Mycophenolate mofetil and rapamycin induce apoptosis in the human monocytic U937 cell line through two different pathways. J Cell Biochem. 2017;118:3480\u20137.","journal-title":"J Cell Biochem"},{"key":"808_CR102","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/08923973.2019.1652913","volume":"41","author":"X Huang","year":"2019","unstructured":"Huang X, Huang Q, He Y, Chen S, Li T. Mycophenolic acid enhanced lipopolysaccharide-induced interleukin-18 release in THP-1 cells via activation of the NLRP3 inflammasome. Immunopharmacol Immunotoxicol. 2019;41:521\u20136.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"808_CR103","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cyto.2008.12.003","volume":"45","author":"Z Liu","year":"2009","unstructured":"Liu Z, Yuan X, Luo Y, He Y, Jiang Y, Chen ZK, et al. Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood. Cytokine. 2009;45:141\u20137.","journal-title":"Cytokine"},{"key":"808_CR104","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/biomedicines9030327","volume":"9","author":"M Schuchardt","year":"2021","unstructured":"Schuchardt M, Herrmann J, Henkel C, Babic M, van der Giet M, Tolle M. Long-term treatment of azathioprine in rats induces vessel mineralization. Biomedicines. 2021;9:327.","journal-title":"Biomedicines"},{"key":"808_CR105","doi-asserted-by":"publisher","first-page":"109042","DOI":"10.1016\/j.reprotox.2025.109042","volume":"137","author":"S Sakr","year":"2025","unstructured":"Sakr S, Ibrahim NM, Ibrahim BA, El Desoky AMZ, Abd Elbaki BT, Eldesoqui M, et al. Fluvastatin mitigates the testicular toxicity of azathioprine via regulating mTOR pathway and restoring autophagy\/apoptosis balance. Reprod Toxicol. 2025;137:109042.","journal-title":"Reprod Toxicol"},{"key":"808_CR106","doi-asserted-by":"publisher","first-page":"R181","DOI":"10.1186\/ar1157","volume":"6","author":"G Palmer","year":"2004","unstructured":"Palmer G, Burger D, Mezin F, Magne D, Gabay C, Dayer JM, et al. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes. Arthritis Res Ther. 2004;6:R181\u20139.","journal-title":"Arthritis Res Ther"},{"key":"808_CR107","doi-asserted-by":"publisher","first-page":"33090","DOI":"10.1038\/s41598-025-17239-z","volume":"15","author":"H Li","year":"2025","unstructured":"Li H, Yang Y, Ma X, Yao X, Ling Y, Ma W. Butin regulates the NLRP3\/CASP-1\/GSDMD pyroptosis axis to inhibit proliferation and pyroptosis in human fibroblast-like synoviocytes of rheumatoid arthritis. Sci Rep. 2025;15:33090.","journal-title":"Sci Rep"},{"key":"808_CR108","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1023\/B:IFLA.0000033025.73363.d3","volume":"28","author":"HW Yao","year":"2004","unstructured":"Yao HW, Li J, Chen JQ, Xu SY. A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells. Inflammation. 2004;28:97\u2013103.","journal-title":"Inflammation"},{"key":"808_CR109","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1440-1797.2012.01563.x","volume":"17","author":"WM Yu","year":"2012","unstructured":"Yu WM, Wang H, Ren XJ, Liu JP, Wang JY. Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats. Nephrology (Carlton). 2012;17:380\u20139.","journal-title":"Nephrology (Carlton)"},{"key":"808_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.631216","volume":"12","author":"M El-Sherbiny","year":"2021","unstructured":"El-Sherbiny M, Atef H, Eladl MA, Mohamed AS, El-Shafey M, Ali HS, et al. Leflunomide induces dose-dependent lung injury in mice via stimulating vimentin and NLRP3 inflammasome production. Front Pharmacol. 2021;12:631216.","journal-title":"Front Pharmacol"},{"key":"808_CR111","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cca.2014.07.039","volume":"438","author":"JY Choe","year":"2015","unstructured":"Choe JY, Kim SK. Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide. Clin Chim Acta. 2015;438:29\u201334.","journal-title":"Clin Chim Acta"},{"key":"808_CR112","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/annrheumdis-2018-214656","volume":"78","author":"N Vazirpanah","year":"2019","unstructured":"Vazirpanah N, Ottria A, van der Linden M, Wichers CGK, Schuiveling M, van Lochem E, et al. mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? Ann Rheum Dis. 2019;78:663\u201371.","journal-title":"Ann Rheum Dis"},{"key":"808_CR113","doi-asserted-by":"publisher","first-page":"40817","DOI":"10.18632\/oncotarget.17256","volume":"8","author":"JH Ko","year":"2017","unstructured":"Ko JH, Yoon S-O, Lee HJ, Oh JY. Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome-p38 MAPK-NF\u03baB pathways in autophagy- and p62-dependent manners. Oncotarget. 2017;8:40817\u201331.","journal-title":"Oncotarget"},{"key":"808_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053078","volume":"8","author":"F Buron","year":"2013","unstructured":"Buron F, Malvezzi P, Villar E, Chauvet C, Janbon B, Denis L, et al. Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study. PLoS ONE. 2013;8:e53078.","journal-title":"PLoS ONE"},{"key":"808_CR115","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1111\/j.1600-6143.2010.03302.x","volume":"10","author":"S Brouard","year":"2010","unstructured":"Brouard S, Puig-Pey I, Lozano JJ, Pallier A, Braud C, Giral M, et al. Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. Am J Transplant. 2010;10:2604\u201314.","journal-title":"Am J Transplant"},{"key":"808_CR116","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.45132","volume":"6","author":"FT Muanda","year":"2023","unstructured":"Muanda FT, Blake PG, Weir MA, Ahmadi F, McArthur E, Sontrop JM, et al. Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease. JAMA Netw Open. 2023;6:e2345132.","journal-title":"JAMA Netw Open"},{"key":"808_CR117","unstructured":"RAPAMUNE (sirolimus). Prescribing information. 2024. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=139. Accessed 3 Sep 2026."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00808-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:02:46Z","timestamp":1789383766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00808-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":117,"alternative-id":["808"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00808-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"18 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TRM has received previous research support from Horizon Therapeutics (Amgen); has served as a consultant for Horizon, Merck, UCB, and Olatec Therapeutics; and receives royalties from Elsevier and UpToDate. TN discloses consulting fees from Crystalys, PK Med, and Sobi. AG has received consulting fees from Atom, Novilla, PK Med, Protalix, Scilex, and Sobi.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval (Appropriate Approvals or Waivers)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Materials (Data Transparency)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability (Software Application or Custom Code)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative AI was not used to create or edit any part of this manuscript.","order":7,"name":"Ethics","label":"Declaration of Generative AI","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors provided substantial contributions to the conception of the work. All authors participated in drafting, revising, and critically reviewing the manuscript for important intellectual content. All authors approved\u00a0the final version of this manuscript to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}